Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2021

01-01-2021 | Lymphoma | Short Communication

Multiple primary cancers (renal papillary, lymphoma and teratoma) and hepatic cysts in association with a pathogenic germline mutation in the MET gene

Author: Julian Adlard

Published in: Familial Cancer | Issue 1/2021

Login to get access

Abstract

Activating germline mutations of the MET gene are associated with hereditary papillary renal cancer. This a very rare autosomal dominant condition, which is usually considered not to display a phenotype of multiple types of malignancy. However, this report describes the case of a man who has been affected with testicular teratoma, diffuse large B-cell lymphoma and multiple hepatic cysts, as well as multiple papillary renal cancers. There is good supporting evidence for roles of over-expression/activity of the HGF/MET ligand-receptor in development of these tumours, raising the possibility of other increased cancer risks associated with activating germline MET gene mutations.
Literature
1.
Schmidt L, Duh F, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73CrossRef
2.
Carlo MI, Hakimi AA, Stewart GD et al (2019) Familial kidney cancer: implications of new syndromes and molecular insights. Eur Urol 76:754–764CrossRef
3.
Tovar EA, Graveel CR (2017) MET in human cancer: germline and somatic mutations. Ann Transl Med 5:205CrossRef
4.
5.
6.
Ricci G, Catizone A (2014) Pleiotropic activities of HGF/c-Met system in testicular physiology: paracrine and endocrine implications. Front Endocrinol 5:38CrossRef
7.
Scheri KC, Leonetti E, Laino L et al (2018) c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors. Oncotarget 9:31842–31860CrossRef
8.
Das MK, Kleppa L, Haugen TB (2019) Functions of genes related to testicular germ cell tumour development. Andrology 7:527–535CrossRef
9.
Zeh N, Wild PJ, Bode PK et al (2013) Retroperitoneal teratoma with somatic malignant transformation: a papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy. BMC Urol 13:9CrossRef
10.
van der Voort R, Taher TE, Derksen PW et al (2000) The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 79:39–90CrossRef
11.
Uddin S, Hussain AR, Ahmed M et al (2010) Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest 90:1346–1356CrossRef
12.
Lam BQ, Dai L, Qin Z (2016) The role of HGF/c-MET signaling pathway in lymphoma. J Hematol Oncol 9:135CrossRef
13.
Bouattour M, Raymond E, Qin S et al (2018) Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology 67:1132–1149CrossRef
14.
Graveel CR, DeGroot JD, Sigler RE et al (2010) Germline met mutations in mice reveal mutation - and background-associated differences in tumor profiles. PLoS ONE 5(10):e13586CrossRef
15.
El Bouchtaoui M, Do Cruzeiro M, Leboeuf C et al (2019) A constitutional activating MET mutation makes the genetic link between malignancies and chronic inflammatory diseases. Clin Cancer Res 25:4504–4515CrossRef
16.
Chen JD, Kearns S, Porter T et al (2001) MET mutation and familial gastric cancer. J Med Genet 38(8):E26CrossRef
17.
Toledo RA, Qin Y, Cheng ZM et al (2016) Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas. Clin Cancer Res 22:2301–2310CrossRef
18.
Whitworth J, Skytte AB, Sunde L et al (2016) Multilocus inherited neoplasia alleles syndrome: a case series and review. JAMA Oncol 2:373–379CrossRef
Metadata
Title
Multiple primary cancers (renal papillary, lymphoma and teratoma) and hepatic cysts in association with a pathogenic germline mutation in the MET gene
Author
Julian Adlard
Publication date
01-01-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2021
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00196-z

Other articles of this Issue 1/2021

Familial Cancer 1/2021 Go to the issue

Short Communication

Two cases of somatic STK11 mosaicism in Danish patients with Peutz–Jeghers syndrome

Original Article

Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series

Original Article

Low accuracy of self-reported family history of melanoma in high-risk patients

Editorial

New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer

Review

Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019

Original Article

Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits